Visceral Leishmaniasis in a patient with rheumatoid arthritis undergoing treatment with methotrexate: Case report and review of the literature

Eur J Rheumatol. 2017 Jun;4(2):139-141. doi: 10.5152/eurjrheum.2017.16066. Epub 2017 Apr 11.

Abstract

There is growing concern regarding the emergence of visceral leishmaniasis (VL), a disseminated parasitic disease caused by protozoa of the genus Leishmania, as an opportunistic infection in immunocompromised patients. This association has been principally studied in the context of human immunodeficiency virus infection, but VL has also been reported in patients undergoing treatment with immunosuppressive medication for various indications. Here a case of VL in a patient with rheumatoid arthritis undergoing treatment with methotrexate and corticosteroid is presented. Despite the rarity of such incidents, physicians should include VL in the differential diagnosis because this infection, if left untreated, is characterized by significant mortality.

Keywords: Visceral leishmaniasis; corticosteroids; immunocompromised patients; methotrexate; rheumatoid arthritis.